|
www.standoutstocks.com: Stocks That Stand Out For Dec. 1st, 2009 Are NNVC, NUBL, CCTR, PGCX, XODG
Dec 01, 2009 (M2 PRESSWIRE via COMTEX) --
www.Standoutstocks.com: Stocks That Standout For Dec. 1st, 2009 are NanoViricides, Inc. (OTC BB: NNVC), NuMobile, Inc. (OTCBB: NUBL), China Crescent Enterprises, Inc. (OTCBB: CCTR), PanGenex Corporation (Pink Sheets: PGCX), Xodtec Group USA, Inc. (OTCBB: XODG)
Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com
_________________________________________________
NanoViricides Files Quarterly Report
WEST HAVEN, Conn., Nov 30, 2009 -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company has filed its quarterly report with the SEC on November 23rd.
The Company reported that it had $4.2 million in cash and cash equivalents as of September 30th, 2009. The Company previously reported that it had successfully raised a total of over $4.3M in different private placement instruments. The details have been disclosed in an SEC Form 8-K filed on October 5, 2009. The Company believes it has sufficient funds to last through the end of December, 2010 at the current rate of expenditure.
The Company now has four commercially important drugs in its pipeline, targeting a total market size of approximately $40 Billion. These drugs target HIV, all Influenzas, viral diseases of the external Eye, and Herpes Simplex viral infections including cold sores and genital herpes (HSV). In addition, the Company has R&D programs in collaborations with reputed institutions against several Neglected Tropical Diseases and agents of interest for Biosecurity. These include hemorrhagic fever viruses such as Ebola/Marburg, Dengue, and Rabies, among others.
Our current drug programs include a pan-influenza drug candidate, "FluCide(TM)". This drug was recently reported to be highly effective against H1N1 influenza in a lethal animal model, leading to an average 14 days survival. It is generally believed that a 14 day survival in this lethal challenge model would suggest indefinite survival in other standardized animal models. FluCide is designed to be effective against all influenza A strains and mutants. We anticipate FluCide to be effective against highly pathogenic avian influenzas such as H7 and H9, the epidemic bird flu virus H5N1 (various clades), the current novel H1N1/2009 virus, seasonal influenza viruses, and their mutations.
The Company has previously reported that its anti-HIV drug candidate was >25X (or >2,500%) more effective than the oral HAART treatment, on a drug load basis. This study employed a standard SCID-hu Thy/Liv mouse model. Human lymphocytes implanted in a mouse, and infected with HIV, are treated with antiviral drugs in this model. It is very important to note that no adverse events were observed in the nanoviricide treated mice, while the HAART-treated mice exhibited clinical signs of side effects. HAART or "highly active anti-retroviral therapy" is a three-drug combination therapy currently in use in human clinical practice, and is regarded as the most effective therapeutic regimen against HIV. If these preliminary results are confirmed in further animal studies and in human clinical trials, the Company believes that HIVCide(TM) could very well result in a "Functional Cure" for HIV/AIDS.
The Company has reported significant progress in its topical nanoviricide eye drops program. This drug is designed to treat most viral infections of the external eye, including adenoviral epidemic kerato-conjunctivitis (EKC) and herpes keratitis.
The Company also recently reported that it has successfully added a new anti-HSV drug program to its pipeline this year. The Company's topical anti-herpes drug candidate has already demonstrated greater than 10,000-fold (>99.99%, or >4 logs) reduction in virus quantity in cell culture models of HSV-1 infection. Animal model studies of topical and genital herpes are planned.
"We are now well poised to further develop our drug candidates with the objective of filing an IND application as soon as possible," said Dr. Eugene Seymour, MD, MPH, CEO of the Company.
About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
NuMobile, Inc. Announces Exclusive Webcast to Update Suggested Fair Value Target Price per Share Highlighting Near-Term Return Potential
Thursday, December 3rd Webcast Agenda Includes Recap of 3rd Quarter Report and Recent $2.2 Million Increase in Assets
CARY, NC, Nov 30, 2009 -- NuMobile, Inc. (OTCBB: NUBL) today announced an on-demand Webcast scheduled for Thursday, December 3rd, 2009 to feature an update of the suggested fair value target price per share highlighting the near-term return on investment (ROI) potential. The Company recently filed its 3rd quarter financial report. The report showed a $2.2 million increase in assets since December 31, 2008. Company CEO Mr. Jim Tilton recently presented an overview of the Company's financial performance explaining the increase in assets as a demonstration of the Company's success in the execution of a new business plan introduced earlier this year. The Webcast on Thursday will also include a recap of the 3rd quarter financial report.
NuMobile's Roll-up Strategy to Build a Portfolio of Software Solutions for Mobile Computing NuMobile is building a portfolio of software solutions for the global mobile computing and smartphone market. NuMobile began its roll-up strategy earlier this year and has acquired two companies with proprietary technology focused on mobile network security. NuMobile has also recently announced LOIs to acquire an additional two companies, Kaizen and SecurAct. Kaizen is an application provider for several markets including SMS, also known as text messaging, MMS, which involves multimedia messaging, and IVR, interactive voice response. SecurAct offers identity management solutions for SaaS and Cloud computing.
A link to the Webcast will be available on the corporate website Investor Relations page at www.numobileinc.com.
NuMobile Information and Email Newsletter To learn more about NuMobile and to sign up for company email alerts, please visit the corporate website at www.numobileinc.com. Interested investors can easily, safely and quickly register to receive these email communications and can safely unsubscribe at any time.
About NuMobile, Inc. (www.numobileinc.com) NuMobile is building a portfolio of security and software solutions for the global mobile computing and smartphone market. Through a roll-up strategy, NuMobile plans to acquire and develop mobile computing solutions for a variety of applications, including mobile banking, for the global marketplace. The demand for mobile security and software applications is being driven in large part by the growing number of mobile phone sales into emerging economies that currently do not have substantial access to the Internet via desktop computing. Already in North America, the Company has also forged a partnership in the Chinese market and is developing a plan for the emerging economies of Latin America and East Africa. NuMobile is a SEC fully-reporting public company listed on the Over-the-Counter Bulletin Board.
"SAFE HARBOR STATEMENT" UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements that involve risks and uncertainties. The statements in this release are forward-looking statements that are made pursuant to safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results, events and performance could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause NuMobile's actual results in future periods to differ materially from results expressed or implied by forward-looking statements. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making investment decisions.
China Crescent Enterprises, Inc. Announces Exclusive Webcast to Update Suggested Fair Value Target Price Per Share Highlighting Near-Term Return Potential
Tuesday, December 1 Webcast Agenda Includes Recap of $30 Million in Revenue and Record $1.8 Million in Net Income for the Nine Months Ending September 30, 2009
DALLAS, TX, Nov 30, 2009 -- China Crescent Enterprises, Inc. (OTCBB: CCTR) has scheduled a shareholder update Webcast for Tuesday, December 1, 2009. The Webcast will feature an update of the suggested fair value target price per share highlighting the near-term return on investment (ROI) potential. Management believes the Company is undervalued with a current share price that reflects a market capitalization less than the current book value.
The Webcast agenda includes a review of the recently released letter to shareholders on the enhanced milestone ROI potential and improved long-term viability of China Crescent. The agenda further includes a recap of the Company's recently filed third quarter 2009 financial results. The Company reported $30 million in revenue through the first nine months of the year, ending September 30, 2009, and record net income of $1.8 million compared to $517k in net income for the same period in 2008. The Company has forecasted profitable revenue growth in 2009 compared to 2008. The Company reported over $40 million in profitable revenue in 2008. A link to the Webcast is scheduled to be posted to the corporate website homepage www.chinacrescent.com upon release.
Sign Up to Receive Regular China Crescent Investor Updates China Crescent sends regular email updates to its opt-in, permission-based email database. Interested investors can easily, safely and quickly register to receive these communications directly on the corporate website homepage (www.chinacrescent.com). Recipients can manage their own email contact profile and safely unsubscribe at any time.
About China Crescent Enterprises, Inc. (www.chinacrescent.com) China Crescent Enterprises, Inc. reported over $40 million in profitable revenue in 2008. The Company is a technology leader in the rapidly developing Chinese market specializing today in software engineering, high quality software development and digital multimedia outsourcing services delivered to customers globally. At the same time, the firm is a systems integrator and value added reseller of major global hardware brands in the Chinese domestic market.
Headquartered in Dallas with operations in Shanghai and Beijing, China Crescent bridges the gap between Western and Eastern business cultures to assist Western clients in realizing the advantages of the high quality, low cost technology products and services available from China. China Crescent also assists Western clients in localizing products and services to realize the tremendous growth potential available by expanding into the Chinese Market.
"SAFE HARBOR STATEMENT" UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements that involve risks and uncertainties. The statements in this release are forward-looking statements that are made pursuant to safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results, events and performance could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause China Crescent's actual results in future periods to differ materially from results expressed or implied by forward-looking statements. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making investment decisions.
PanGenex Signs Licensing Deal to the Enter the $600 Million Spirulla Market
To Develop Retail Products Using the All-Natural, Superfood Spirulla CLEARWATER, Fla., Nov 30, 2009 -- PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has solidified plans to expand its retail product line with the addition of spirulla. Spirulla, a blue green algae, is an abundant and sustainable natural source of protein, essential fatty acids, vitamins, B12 and minerals that has been used as a dietary health supplement for centuries. Through a licensing agreement with Greenr U Corp., PanGenex has access to a state-of-the-art algae growing system to begin producing its own high-quality spirulla. The Company plans to incorporate spirulla into select product lines as well as develop an array of new, heart-healthy nutraceutical and dietary supplements featuring spirulla.
"Spirulla is considered a 'superfood,' packed with 100% natural energy-boosting ingredients. We believe a move into the $600 million spirulla market is a major step toward sustaining long-term growth," said John Stanton, Chairman of PanGenex. "Our goal is to reach sales of $2 million in our first year of production and increase exponentially as growing acreage is added and our additional products are brought to market." PanGenex plans to develop a variety of spirulla-infused heath products ideal for health-conscious consumers, aging baby-boomers, vegetarians and more. "We believe we can produce the highest quantity and purest form of spirulla available on the market today. Our algae will be grown in nutrient-enhanced fresh water within a closed loop vertical system, thus avoiding the contamination typical of outdoor ponds. We expect to deliver our first products from this production facility in early summer 2010. Our scientists and product consultants are researching strains for other specialized beneficial use that a dedicated facility will allow us to grow to our product specifications." PanGenex initially expects to grow approximately 40,000 gallons of oil or 10,000 lbs of spirulla powders per acre per year. Dry powder spirulla sells for in excess of $50 per lb, while other specialized strains sell for in excess of $400 per lb. Other uses for algal oils and powder include protein enhancement products as part of the $27 billion sports nutrition market and in oil capsules as a replacement for certain types of liquid fish oil capsules. PanGenex products will be marketed to health and whole food stores and through its various existing outlets.
About PanGenex Corporation PanGenex pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels for review by the FDA without incidence. PanGenex products are currently sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.
Disclaimer: CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Xodtec Group USA, Inc. Has Signed an Energy Service Contract with a Grand Resort to Retrofit Energy and LED Lighting Systems
CARSON CITY, Nev., Nov 30, 2009 -- Xodtec Group USA, Inc. (OTCBB: XODG) (the "Company"), a market leader in LED lighting, announced today that it has signed an energy service contract with West Lake Resortopia to act as its energy service company ("ESCO") and provide a broad range of comprehensive energy solutions including illumination and artistic lighting for environmental and architectural decoration. West Lake Resortopia is a resort which incorporates the mountains and natural scenery surrounding it in Miaoli County, Taiwan. By introducing integrated energy solutions, Resortopia hopes to promote its corporate image by reducing its electricity expense and carbon emissions to provide a cleaner environment.
Resortopia will purchase a large number of indoor, outdoor, color-changing artistic light lamps and fixtures from Xodtec, which will also retrofit Resortopia's illumination and decorative lighting systems. The project is divided into three phases; the ongoing first phase is about providing an integrated energy-efficient hot water system, expected to generate revenue in excess of $1,500,000US; the second and third phases are about providing LED illumination and ambience artistic lighting, currently under planning and expected to be executed at the end of year 2009. The estimated gross revenue of this project is approximately in excess of $4,687,000US.
"West Lake Resortopia is a comprehensive project, we will not merely provide LED lighting products, but also engineer integrated energy solutions," stated Curtis Su, Chairman of Xodtec Group USA, Inc. "This is a challenging project for us, combining optimal energy-efficient lighting solutions and outstanding artistic lighting effects which we hope will demonstrate our versatility in the lighting industry." About Xodtec Group USA, Inc.: Xodtec, a Nevada corporation, is an Energy-Saving Lighting Solutions Provider based in Taiwan. Xodtec provides high performance and cost-effective energy-saving LED solutions and traditional lighting products for private companies, public facilities, residential communities, factories and households, providing optimal energy-saving solutions that meet today's energy management requirements. Please visit our website http://www.xodtec.com.tw/xodtec_en/ for detailed company information.
Safe Harbor Statement: This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Xodtec Group USA, Inc., are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the Company from time to time with the United States Securities and Exchange Commission.
About Standoutstocks.com www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.
Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx
CONTACT: Jason A. Hilton, Standout Stocks
Tel: +1 585 729 8809
e-mail: Jason@Newmediaadvisorsllc.com
e-mail: info@standoutstocks.com
WWW: http://www.standoutstocks.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
[ Back To Contact Center Solutions Homepage's Homepage ]
|
NextiraOne Obtains Cisco's Unified Contact Centre Enterprise ATP Status 
EXTOL Appoints Michael DeCosta Vice President of Sales
NEW Consolidating Infrastructures: IT's New Call to Business [white paper]
